NasdaqGM - Nasdaq Real Time Price USD

CorMedix Inc. (CRMD)

5.32 +0.09 (+1.72%)

At close: November 6 at 4:00:01 PM EST

5.35 +0.03 (+0.56%)

After hours: November 6 at 7:54:28 PM EST

Trade CRMD on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for CRMD

1h ago Powered by Yahoo Scout

CorMedix reaffirmed 2026 revenue guidance of $325 million to $345 millionand reported approximately $355 million in cash. Investors are focused on DefenCath reimbursement changes, while the company’s November 12earnings release remains the next major catalyst.

Previous Close 5.23
Open 5.25
Bid 5.35 x 200
Ask 9.71 x 200
Day's Range 5.10 - 5.34
52 Week Range 5.10 - 13.02
Volume 1,616,054
Avg. Volume 1,345,645
Market Cap (intraday) 414.664M
Beta (5Y Monthly) 1.48
PE Ratio (TTM) 2.60
EPS (TTM) 2.05
Earnings Date Nov 12, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 14.83
Motley Fool Rating Bullish

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

cormedix.com

191

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CRMD

54.26%

S&P 500 (^GSPC)

7.76%

1-Year Return

CRMD

50.65%

S&P 500 (^GSPC)

9.77%

3-Year Return

CRMD

54.20%

S&P 500 (^GSPC)

68.96%

5-Year Return

CRMD

2.03%

S&P 500 (^GSPC)

57.04%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q1 FY26

Revenue 127.43M

Earnings 38.6M

Profit Margin 30.29%

FY25

FY26

50M

100M

20.0%

40.0%

60.0%

80.0%

100.0%

Analyst Price Targets

12.00

14.83 Average

5.32 Current

19.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 11/2/2026

Analyst Needham

Rating Action Maintains

Rating Buy

Price Action Lowers

Price Target 15 -> 12

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

40.49%
Return on Assets (ttm)

24.56%
Return on Equity (ttm)

54.93%
Revenue (ttm)

462.25M
Net Income Avi to Common (ttm)

186.02M
Diluted EPS (ttm)

2.05

Balance Sheet and Cash Flow

Total Cash (mrq)

256.69M
Total Debt/Equity (mrq)

32.00%
Levered Free Cash Flow (ttm)

178.14M

TLPH Talphera, Inc.

1.0500 +4.95%

VTVT vTv Therapeutics Inc.

21.03 -4.09%

OGEN Oragenics, Inc.

0.3492 +0.06%

ALDX Aldeyra Therapeutics, Inc.

0.6337 +13.65%

CAPR Capricor Therapeutics, Inc.

9.00 +4.07%

U.S. markets closed

CorMedix Inc. (CRMD)

Trading disclosure

-6.67%

-26.92%

-33.91%

-54.26%

-50.65%

-2.03%

-66.75%

What's happening with CRMD?

CorMedix Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch